On this page
Short answer Starting cell therapy: what to know Common questions Related questions SourcesAfamitresgene autoleucel (brand name Tecelra) is a one-time engineered T-cell therapy used to treat advanced synovial sarcoma, a rare soft tissue cancer, in adults who have already received chemotherapy.
It is used when the cancer cannot be removed with surgery or has spread to other parts of the body. Two lab results decide whether you can receive it: your tumor has to make a protein called MAGE-A4, and your blood has to carry a specific HLA-A*02 tissue type. Your own T cells are collected through apheresis, modified in a lab to target the tumor, and given back to you as a single infusion after a short course of lymphodepleting chemotherapy. It is given only at certified treatment centers, because you need close monitoring for cytokine release syndrome, low blood counts, and infection in the weeks that follow. A sarcoma specialist orders the testing and decides whether this therapy fits your situation.
Starting cell therapy: what to know
Common questions
What is Afamitresgene Autoleucel Injection used for?
Afamitresgene autoleucel (Tecelra) treats advanced synovial sarcoma, a rare cancer of the soft tissue. It is approved for adults with disease that cannot be removed by surgery or that has spread, and who have already had chemotherapy. It is not an option for everyone with this cancer. Your tumor must express the MAGE-A4 protein and you must carry a specific HLA-A*02 tissue type, both confirmed by lab testing first. Your own T cells are collected, engineered to recognize the tumor, and returned as a single infusion after short lymphodepleting chemotherapy. Care happens at certified centers with monitoring for cytokine release syndrome, low blood counts, and infection. A sarcoma specialist decides if it fits your case.